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Abstract
Background: Serum creatinine and symmetric dimethylarginine (SDMA) are used as sur-
rogate markers of glomerular filtration rate (GFR) in clinical practice. Data pertaining to
the correlations between GFR, SDMA, and serum creatinine in client-owned dogs are
limited.
Objectives: To describe the relationship between GFR, SDMA, and serum creatinine
in a population of client-owned dogs, and to compare clinical utility of SDMA to GFR
estimation for detecting pre-azotemic chronic kidney disease.
Animals: Medical records of 119 dogs that had GFR estimation performed via serum
iohexol clearance between 2012 and 2017.
Methods: Prospective study using archived samples. GFR, SDMA, and serum creati-
nine results were reviewed and submitting practices contacted for outcome data. All
dogs included in the study population were non-azotemic. Correlations between
GFR, SDMA, and serum creatinine were determined by regression analysis. Sensitiv-
ity, specificity, and positive and negative likelihood ratios of different cutoffs for
SDMA and serum creatinine for detecting decreased GFR were calculated, using a
95% confidence interval.
Results: Serum creatinine and SDMA were moderately correlated with GFR (R2 = 0.52
and 0.27, respectively, P < .0001) and with each other (R2 = 0.33, P < .0001). SDMA >14
μg/dL was sensitive (90%) but nonspecific (50%) for detecting a ≥40% decrease in GFR.
Optimal SDMA concentration cutoff for detecting a ≥40% GFR decrease was >18 μg/dL
(sensitivity 90%, specificity 83%).
Conclusions and Clinical Importance: In non-azotemic dogs being screened for
decreased renal function, using a cutoff of >18 μg/dL rather than >14 μg/dL increases
the specificity of SDMA, without compromising sensitivity.
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; GFR, glomerular filtration rate; HPCE, high-performance capillary electrophoresis; LR+, positive likelihood ratio;
LR−, negative likelihood ratio; ROC, receiver operating characteristic; RVC, Royal Veterinary College; SDMA, symmetric dimethylarginine.
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1 | INTRODUCTION
Glomerular filtration rate (GFR) estimation is regarded as the gold
standard method for assessing renal function, as it is directly propor-
tional to renal mass.1 Although direct measurement of GFR is not pos-
sible, it can be estimated by assessing the clearance of a marker of
GFR.2 Measuring the plasma clearance of iohexol has become a
widely used means of estimating GFR due to its availability, cost, and
ease of use.3-12 Measuring the plasma clearance of iohexol using a
limited sampling technique has been described in dogs.13
Although GFR estimation is the gold standard for assessing renal
function, measurement of serum creatinine, a surrogate marker of GFR,
remains themainmeans of assessing renal function in dogs in clinical prac-
tice.14However, using serumcreatinine as amarker ofGFRhas limitations.
The relationship between serum creatinine and GFR is exponential, such
that serum creatinine has limited sensitivity for the early detection of
declining renal function.15 In addition, lean body mass has an effect on
serum creatinine concentrations,16 making assessment of GFR in well-
muscled or cachexic animals challenging. Furthermore, false increases in
serum creatinine concentrations are possible with certain assays,17 and in
male dogs, a small amount of creatinine is secreted in the renal tubules.18
Recent studies indicate that symmetric dimethylarginine (SDMA)
could be a promising marker of GFR in dogs.19,20 Symmetric
dimethylarginine is produced by the breakdown of proteins, the argi-
nine residues of which have been posttranslationally methylated and
is excreted primarily (≥90%) by renal clearance.21,22 Unlike serum cre-
atinine, SDMA is unaffected by lean body mass.16 Symmetric
dimethylarginine has an exponential relationship with GFR but could
be a more sensitive marker of declining GFR than serum creatinine.19
A caveat is that data pertaining to the effects of concurrent disease
on SDMA remain somewhat limited.
In dogs with X-linked hereditary nephropathy, SDMA increases as
the disease progresses, correlating with increases in serum creatinine
and decreasing GFR.19 In this population of dogs, SDMA detects, on
average, a <20% decrease in GFR- earlier than serum creatinine using
any comparison method.19 In addition, serum SDMA increases before
serum creatinine by a mean of 9.8 months (range, 2.2-27 months) in
dogs with chronic kidney disease (CKD).20 Although the 2 aforemen-
tioned studies described the relationship between GFR, SDMA, and
serum creatinine, the study populations in both cases were relatively
small populations of research colony dogs. Data relating to the rela-
tionship between GFR, SDMA, and serum creatinine in a general pop-
ulation of client-owned dogs in a clinical setting where kidney disease
is suspected based on their clinical presentation are lacking.
The aim of this study was to describe the relationship between GFR,
SDMA, and serum creatinine in a population of client-owned dogs pre-
senting to both referral and first-opinion practice and to compare the
clinical utility of SDMA to the gold standard of GFR estimation via serum
iohexol clearance for the detection of pre-azotemic CKD.
2 | MATERIALS AND METHODS
2.1 | Data acquisition and analysis
The medical records of dogs that had samples submitted for GFR esti-
mation via iohexol clearance to the Royal Veterinary College (RVC)
from September 3, 2012, to April 11, 2017, were assessed. The pro-
ject was reviewed and approved by the RVC clinical research and ethi-
cal review board which allowed for access to joint iohexol clearance
test submission forms held by deltaDOT Ltd. and the RVC, with sub-
sequent submission of serum samples for SDMA and serum creatinine
measurement via batch analysis to Idexx Laboratories Ltd. Addition-
ally, contact with the veterinarians for access to the clinical records of
the dogs under investigation and for completion of a short question-
naire regarding case outcomes was approved. This contact was per-
formed before final implementation of the General Data Proection
Regulation (EU) 2016/679.
2.2 | Iohexol clearance protocol
A standard protocol was used for performing the iohexol clearance
tests via a limited sampling technique.23 A single dose of iohexol
(Omnipaque™ 300) was administered at 300 mg iodine/kg intrave-
nously through an IV catheter. Blood was collected at precisely 2, 3,
and 4 hours after iohexol administration, and samples were subse-
quently centrifuged. Serum iohexol concentration for each serum sam-
ple was measured using deltaDOT Ltd.'s previously validated high-
performance capillary electrophoresis method.24 Glomerular filtration
rate was estimated from the iohexol clearance data by application of a
compartmental model and a dog-specific correction formula,13 normal-
ized to body weight in kilograms. For data analysis, dogs were divided
into the 4 weight quartiles13: Category 1:1.8-12.4 kg, Category
2:13.2-25.5 kg, Category 3:25.7-31.6 kg, and Category 4:32.0-70.3 kg.
In the event that a canine body weight did not fall within the range of
1 of these body weight categories, the dog was included in the body
weight category to which its body weight was closest. The estimated
GFR of each dog was compared to the mean GFR of their respective
body weight categories13: 2.89 mL/kg/min for Category 1, 2.4 mL/kg/
min for Category 2, 2.16 mL/kg/min for Category 3, and 2.25 mL/kg/
min for Category 4. Glomerular filtration rate estimation results were
interpreted in light of the following categorization criteria:23 GFR group
1: GFR increased or <20% decreased from the mean GFR of the body
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weight category, kidney disease considered excluded or very unlikely as
an etiology for presenting clinical signs; GFR group 2: ≥20% but <30%
decrease in GFR from the mean GFR of the body weight category, kid-
ney disease considered possible but unconfirmed as an etiology for pre-
senting clinical signs; GFR group 3: ≥30% but <40% decrease in GFR
from the mean GFR of the body weight category, kidney disease consid-
ered likely as an etiology for presenting clinical signs; GFR group 4:
≥40% decrease in GFR from the mean GFR of the body weight category,
kidney disease considered almost certain as an etiology for presenting
clinical signs.
Using the baseline serum sample that was submitted for GFR estima-
tion via iohexol clearance testing, SDMA and serum creatinine concentra-
tions were measured. The serum used was collected before iohexol
administration in all cases. After storage in a−80C freezer for amedian of
166 days (range, 9-1360 days), all samples were submitted to Idexx Labo-
ratories Ltd. All serum creatinine samples were sent to Idexx Wetherby
(UK; analyzer: Olympus AU5800, method: Jaffe kinetic without
deproteination). Symmetric dimethylarginine samples were sent to either
IdexxWetherby (UK) or Idexx Ludwigsburg (Germany). Identical analyzers
and methodology were used to measure SDMA in both laboratories (ana-
lyzer: Olympus AU5800, method: enzyme immunoassay). The reference
intervals for SDMA and serum creatinine used in this study were set at
0-14 μg/dL and 0.23-1.63 mg/dL, respectively, on September 29, 2017.
Based on the Idexx reference interval for serum creatinine, only data from
dogs that were non-azotemicwere taken forward for further analysis.
Reasons for performing GFR estimation in this population are
described in a separate publication evaluating the clinical utility of
GFR estimation in dogs,23 and included screening for pre-azotemic
CKD, confirmation of azotemic CKD, screening for pre-azotemic acute
kidney injury, and assessing the need for carboplatin dose adjustment
in patients undergoing chemotherapy. As part of that study, the
veterinarian(s) who submitted each sample set for iohexol clearance
to be measured were contacted via email and asked to complete a
short questionnaire regarding case outcomes. Data collected included
status (ie, alive/dead), date of euthanasia/death, reason for euthana-
sia/death if known, and whether or not a diagnosis was reached for
the clinical signs/ routine laboratory findings that prompted GFR esti-
mation. If no response to the questionnaire was received or the
answers were insufficient to provide outcome information, veterinar-
ians were contacted directly by telephone to request the full clinical
history and laboratory reports for the dogs in question from the time
of iohexol clearance sample submission to the time of follow-up.
2.3 | Statistical analysis
Data are presented as median (range) unless otherwise stated. GFR
estimation results were expressed as percent deviation from the mean
GFR of that canine body weight category13 and interpreted in light of
the defined categorization criteria.23 Statistical analyses were per-
formed using statistical software Prism 8 (Prism 6 for Mac OS X, Gra-
phPad Software Inc, La Jolla, California). To investigate the
associations between SDMA and GFR, serum creatinine concentration
and GFR, and SDMA and serum creatinine concentration, SDMA and
serum creatinine results were plotted against GFR data and against
each other. Best-fit equations were derived from the resulting data
plots in order to measure the associations between variables. Data
from the 119 dogs for which GFR results and creatinine and/or SDMA
results were available were included in the calculation of these
associations.
The sensitivity, specificity, positive likelihood ratio (LR+) and nega-
tive likelihood ratio (LR−) of different cutoff points for SDMA (>10, >12,
>14, >16, >18, and >20 μg/dL) and different cutoff points for serum cre-
atinine (≥1.0, ≥1.1, ≥1.2, ≥1.3, ≥1.4, and ≥1.5 mg/dL) for detecting
decreases in GFR (GFR decreases of ≥20%, ≥30%, and ≥ 40% below the
mean GFR of the patient's body weight category, respectively) were
manually calculated, using a 95% confidence interval (CI). For calculation
of sensitivity, specificity, LR+, and LR−, only those dogs for which GFR,
SDMA, and serum creatinine results were simultaneously available were
included (n = 90).
Receiver operating characteristic (ROC) curves were developed to
assess the trade-off between the sensitivity and (1 − specificity)
across a series of cutoff points for SDMA (>10, >12, >14, >16, >18,
and >20 μg/dL) and serum creatinine (≥1.0, ≥1.1, ≥1.2, ≥1.3, ≥1.4,
and ≥ 1.5 mg/dL) to detect decreases in GFR of ≥20%, ≥30% and
≥40% below the mean GFR of a patient's body weight category.
Based off ROC curve data, Youden's J statistic was used to determine
optimal cutoff points.
3 | RESULTS
3.1 | GFR, serum creatinine, and SDMA results
A total of 132 dogs had samples submitted for GFR estimation
between September 3, 2012, and April 11, 2017. The characteristics
of this study population are described.23 Serum creatinine data were
available for 100 of 132 (76%) dogs. In 4 of the 100 (4%) dogs for
which serum creatinine was available, serum creatinine was above the
upper limit of the reference interval (>1.63 mg/dL). The 4 azotemic
dogs were excluded from the data set and from further analysis, leaving
a total of 128 dogs in the data set. After exclusion of the 4 azotemic
dogs, serum creatinine data were available for 96 of 128 (75%) dogs.
Symmetric dimethylarginine was available for 113 of 128 (88%) dogs
with concurrent SDMA and creatinine available for 90 (70%) dogs.
In the 119 dogs for which either serum creatinine or SDMA was
available, median GFR was 2.19 mL/kg/min across all body weight
categories with a range of 1.16-4.04 mL/kg/min. Percentage devia-
tion from the mean of the body weight category ranged from −55%
to +68.0% with a median deviation of −11.2% from the mean. In
42 of 119 (35%) dogs, the percentage deviation from the mean of the
body weight category was ≥20% decreased.
Median serum creatinine for all 96 non-azotemic dogs for which
it was available was 1.11 mg/dL (range, 0.45-1.59 mg/dL), whereas
median SDMA for all 113 dogs for which it was available was 15 μg/
dL (range, 6-27 μg/dL).
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In 59 of 113 (52%) dogs, SDMA was above the upper limits of the
reference interval (>14 μg/dL). The median SDMA for these 59 dogs was
17 μg/dL (range, 15-27 μg/dL). Median change in GFR from the mean
GFR for the body weight category in the 59 dogs with increased SMDA
was −18.8% (range, −55% to +40.8%). In the 59 cases with increased
SDMA, GFR was increased or <20% decreased below the mean GFR for
the canine body weight category in 32 of 59 (54%) of cases. Further
description of SDMA and serum creatinine results by GFR category is
provided in Table 1.
3.2 | The relationship between SDMA and serum
creatinine concentration with GFR
Serum creatinine and SDMA were moderately correlated with GFR
(R2 = 0.52 and 0.27 respectively, P < .0001) and with each other
(R2 = 0.33, P < .0001). The relationships between GFR and serum cre-
atinine (Figure 1), GFR and SDMA (Figure 2), and serum creatinine
and SDMA (Figure 3) were all linear.
3.3 | Utility of SDMA for detecting decreases
in GFR
The manually calculated sensitivity and specificity of different cutoff
points for SDMA (>10, >12, >14, >16, >18, and >20 μg/dL) and differ-
ent cutoff points for serum creatinine (≥1.0, ≥1.1, ≥1.2, ≥1.3, ≥1.4,
and ≥ 1.5 mg/dL) for detecting decreases in GFR (GFR decreases of
≥20%, ≥30% and ≥ 40% below the mean GFR of the canine body
weight category respectively) are outlined in Table 2. The LR+ and LR
− of these cutoff points for SDMA and serum creatinine for detecting
decreases in GFR were manually calculated according to the following
equations and are outlined in Table 3.
The LR+ is the probability of a dog with decreased GFR to have the
analyte exceeding cutoff divided by the probability of a dog with normal
GFR to have the same analyte exceeding cutoff (LR+ = sensitivity1−specificityÞ. A LR+
greater than 1 indicates that the test result is associated with
decreased GFR. The higher the LR+, the stronger the association. The
LR− is the probability of a dog with decreased GFR to have the analyte
below the cutoff divided by the probability of a dog with normal GFR to
have the same analyte below the cutoff (LR−= 1−sensitivityspecificity Þ. A likelihood
ratio less than 1 indicates that the result is associated with absence of
the disease. The lower the LR−, the stronger the exclusion.
TABLE 1 Number of patients falling into each GFR category with normal (≤14 μg/dL) or increased (>14 μg/dL) SDMA, and serum creatinine
concentrations above and below the cutoff for stage 1 chronic kidney disease (≥1.4 mg/dL), as per the International Renal Interest Society (IRIS)
guidelines25
Variables All GFR categories (total) GFR " or # <20% GFR # ≥20 but <30% GFR # ≥30 but <40% GFR # ≥40
SDMA ≤14 μg/dL
Number 54 43 (80%) 3 (5.5%) 5 (9%) 3 (5.5%)
Median SDMA μg/dL (range) 11 (6-14) 11 (6-14) 11 (10-12) 13 (11-14) 12 (12-14)
SDMA >14 μg/dL
Number 59 32 (54.0%) 10 (17.0%) 5 (8.5%) 12 (20.5%)
Median SDMA μg/dL (range) 17 (15-27) 16 (15-24) 18 (15-22) 21 (16-25) 21 (16-27)
Creatinine <1.4 mg/dL
Number 82 59 (72%) 11 (13%) 8 (10%) 4 (5%)
Median creatinine mg/dL (range) 1.05 (0.45-1.39) 0.96 (0.45-1.37) 1.19 (0.80-1.39) 1.33 (0.90-1.39) 1.23 (0.87-1.38)
Creatinine ≥1.4 mg/dL
Number 14 2 (14.3%) 3 (21.4%) 2 (14.3%) 7 (50.0%)
Median creatinine mg/dL (range) 1.46 (1.40-1.59) 1.45 (1.44-1.45) 1.58 (1.55-1.59) 1.47 (1.46-1.48) 1.46 (1.40-1.50)
Note: Glomerular filtration rate results are expressed as per the categories defined by McKenna et al23: GFR group 1: GFR increased or <20% decreased
from the mean GFR of the body weight category, kidney disease considered excluded/or very unlikely; GFR group 2: ≥20% but <30% decrease in GFR,
kidney disease considered possible but unconfirmed; GFR group 3: ≥30% but <40% decrease in GFR, kidney disease considered likely; GFR group 4: ≥40%
decrease in GFR, kidney disease considered almost certain.
Abbreviations: GFR, glomerular filtration rate; SDMA, symmetric dimethylarginine.
F IGURE 1 Relationship between serum iohexol clearance and
serum creatinine. GFR, glomerular filtration rate
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A ROC curve assessing the trade-off between sensitivity and
(1 − specificity) across the range of SDMA concentrations (including
the cutoff points of >10, >12, >14, >16, >18, and >20 μg/dL) to detect
decreases in GFR below the mean GFR of a canine body weight cate-
gory of ≥20%, ≥30%, and ≥40% is presented in Figure 4. The area
under the curve for SDMA assessing for a decrease in GFR ≥20% was
0.76, 0.77 for assessing for a GFR decrease ≥30%, and 0.88 for
assessing for a GFR decrease ≥40%. Based off ROC curve data, using
Youden's J statistic, the optimal SDMA cutoff for assessing for a GFR
decrease of ≥20% was >18 μg/dL (sensitivity 52% [95% CI, 33-70],
specificity 88% [95% CI, 77-95]). The optimal SDMA cutoff for
assessing for a GFR decrease of ≥30% was >20 μg/dL (sensitivity 56%
[95% CI, 31-78], specificity 92% [95% CI, 83-97]), and optimal SDMA
cutoff for assessing for a GFR decrease of ≥40% was >18 μg/dL (sen-
sitivity 90% [95% CI, 55-100], specificity 83% [95% CI, 72-90]).
A ROC curve assessing the trade-off between sensitivity and (1
− specificity) across the range of serum creatinine concentrations (includ-
ing the cutoff points of ≥1.0, ≥1.1, ≥1.2, ≥1.3, ≥1.4, and ≥1.5 mg/dL) to
detect decreases in GFR below the mean GFR of a canine body weight
category of ≥20%, ≥30% and ≥40% is presented in Figure 5. The area
under the curve for serum creatinine assessing for a decrease in GFR
≥20% was 0.85, 0.85 for assessing for a GFR decrease ≥30%, and 0.86
for assessing for a GFR decrease ≥40%. Based off ROC curve data, using
Youden's J statistic, the optimal serum creatinine concentration cutoff
for assessing for a GFR decrease of ≥20% was ≥1.14 mg/dL (sensitivity
81% [95% CI, 63-93], specificity 76% [95% CI, 63-86]). The optimal
serum creatinine concentration for assessing for a GFR decrease of
≥30% was ≥1.31 mg/dL (sensitivity 83% [95% CI, 59-96], specificity
86% [95% CI, 76-93]) and optimal serum creatinine concentration for
assessing for a GFR decrease of ≥40% was ≥1.36 mg/dL (sensitivity 80%
[95% CI 44-98], specificity 89% [95% CI 80-95]).
Nine of 90 (10%) dogs had concurrent SDMA >18 μg/dL and
serum creatinine ≥1.36 mg/dL documented. Manually calculated
F IGURE 2 Relationship between serum iohexol clearance and
serum symmetric dimethylarginine (SDMA)
F IGURE 3 Relationship between serum symmetric
dimethylarginine (SDMA) and serum creatinine
TABLE 2 Ability of different cutoff points of SDMA and serum creatinine to detect different categories of %GFR decrease below the mean
GFR of the dog's body weight category
Variables
Sample
size
Sensitivity
%GFR # ≥20%
(95% CI)
Specificity
%GFR # ≥20%
(95% CI)
Sensitivity
%GFR # ≥30%
(95% CI)
Specificity
%GFR # ≥30%
(95% CI)
Sensitivity
%GFR # ≥40%
(95% CI)
Specificity
%GFR # ≥40%
(95% CI)
SDMA > 10 μg/dL 90 96.8 (83.3-99.9) 22.0 (12.3-34.7) 94.7 (74.0-99.9) 18.3 (10.1-29.3) 90.9 (58.7-99.8) 16.5 (9.1-26.5)
SDMA > 12 μg/dL 90 83.9 (66.3-94.6) 42.4 (29.6-55.9) 88.9 (65.3-98.6) 38.9 (27.6-51.1) 90.0 (55.5-99.8) 36.3 (25.8-47.8)
SDMA > 14 μg/dL 90 74.2 (55.4-88.1) 55.9 (42.4-68.8) 72.2 (46.5-90.3) 50.0 (38.0-62.0) 90.0 (55.5-99.8) 50.0 (38.6-61.4)
SDMA > 16 μg/dL 90 62.5 (43.7-78.9) 79.3 (66.7-88.8) 66.7 (41.0-86.7) 72.2 (60.4-82.1) 90.0 (55.5-99.8) 71.3 (60.1-80.8)
SDMA > 18 μg/dL 90 45.2 (27.3-64.0) 94.9 (85.9-98.9) 55.6 (30.8-78.5) 90.3 (81.0-96.0) 80.0 (44.4-97.5) 88.8 (79.7-94.7)
SDMA > 20 μg/dL 90 29.0 (14.2-48.0) 94.9 (85.9–98.9) 44.4 (21.5-69.2) 94.4 (86.4-98.5) 60.0 (26.2-87.8) 92.5 (84.4-97.2)
Creatinine ≥ 1.0 mg/dL 90 87.1 (70.2-96.4) 52.5 (39.1-65.7) 88.9 (65.3-98.6) 45.8 (34.0-58.0) 90.0 (55.5-99.8) 42.5 (31.5-54.1)
Creatinine ≥ 1.1 mg/dL 90 83.9 (66.3-94.6) 67.8 (54.4-79.4) 88.9 (65.3-98.6) 59.7 (47.5-71.1) 90.0 (55.5-99.8) 55.0 (43.5-66.2)
Creatinine ≥ 1.2 mg/dL 90 71.0 (52.0-85.8) 81.4 (69.1-90.3) 83.3 (58.6-96.4) 75.0 (63.4-84.5) 90.0 (55.5-99.8) 70.0 (58.7-79.7)
Creatinine ≥ 1.3 mg/dL 90 64.5 (45.4-80.8) 88.1 (77.1-95.1) 83.3 (58.6-96.4) 83.3 (72.7-91.1) 90.0 (55.5-99.8) 77.5 (66.8-86.1)
Creatinine ≥ 1.4 mg/dL 90 35.5 (19.2-54.6) 96.6 (88.3-99.6) 50.0 (26.0-74.0) 94.4 (86.4-98.5) 70.0 (34.8-93.3) 92.5 (84.4-97.2)
Creatinine ≥ 1.5 mg/dL 90 9.7 (2.0-25.8) 100.0 (93.9-100.0) 5.6 (0.1-27.3) 97.2 (90.3-99.7) 10.0 (0.3-44.5) 97.5 (91.3-99.7)
Abbreviations: GFR, glomerular filtration rate; SDMA, symmetric dimethylarginine.
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sensitivity and specificity of concurrent SDMA >18 μg/dL and serum
creatinine ≥1.36 mg/dL for detection of a GFR decrease of ≥40%
below mean were 70% (95% CI, 35-93) and 98% (95% CI, 91-100),
respectively. Manually calculated LR+ and LR− of concurrent SDMA
>18 μg/dL and serum creatinine ≥1.36 mg/dL for detection of a GFR
decrease of ≥40% below mean were 28.0 (95% CI, 6.7-116.7) and 0.3
(95% CI, 0.1-0.8) respectively.
Out of the 59 dogs that had increased SDMA (>14 μg/dL) mea-
sured, in 32 dogs (54%) their GFR result was not considered consis-
tent with renal disease (GFR increased or <20% decreased from the
mean GFR of their body weight category). Out of these 32 dogs,
reviewing the available follow-up data, a final diagnosis was available
for 23 (71.8%), with a median time to follow-up of 344 days (range,
2-951 days). A range of different final diagnoses for the dogs' pre-
senting clinical signs were obtained: psychogenic polydipsia (n = 8), idio-
pathic dermatopathy (n = 5), clinically normal (n = 3), central diabetes
insipidus (n = 2), colonic adenocarcinoma (n = 1), urinary tract infection
(n = 1), urinary incontinence (n = 1), pyelonephritis (n = 1), and renal mass
(n = 1). Follow-up data on dogs that had a decrease in GFR ≥20% below
mean is further discussed in a separate publication.23
4 | DISCUSSION
The relationships between GFR and both serum creatinine and SDMA
were linear. This contrasts with data from a previous study,19 where the
TABLE 3 Positive likelihood ratios (LR+) and negative likelihood ratios (LR−) of different cutoff points for SDMA and serum creatinine
concentration to detect different categories of %GFR decrease below the mean GFR of the patient's body weight category
Variables
Sample
size
LR+
%GFR # ≥20%
(95% CI)
LR−
%GFR # ≥20%
(95% CI)
LR+
%GFR # ≥30%
(95% CI)
LR−
%GFR # ≥30%
(95% CI)
LR+
%GFR # ≥40%
(95% CI)
LR−
%GFR # ≥40%
(95% CI)
SDMA > 10 μg/dL 90 1.2 (1.1-1.4) 0.2 (0.0-1.1) 1.2 (1.0-1.4) 0.3 (0.0-2.2) 1.1 (0.9-1.3) 0.6 (0.1-3.8)
SDMA > 12 μg/dL 90 1.5 (1.1-1.9) 0.4 (0.2-0.9) 1.5 (1.1-1.9) 0.3 (0.1-1.1) 1.4 (1.1-1.8) 0.3 (0.0-1.8)
SDMA > 14 μg/dL 90 1.7 (1.2-2.4) 0.5 (0.2-0.9) 1.4 (1.0-2.1) 0.6 (0.3-1.2) 1.8 (1.3-2.4) 0.2 (0.0-1.3)
SDMA > 16 μg/dL 90 3.0 (1.7-5.1) 0.5 (0.3-0.8) 2.4 (1.5-3.9) 0.5 (0.2-0.9) 3.1 (2.1-4.7) 0.1 (0.0-0.9)
SDMA > 18 μg/dL 90 8.9 (2.8-28.6) 0.6 (0.4-0.8) 5.7 (2.5-12.9) 0.5 (0.3-0.8) 7.1 (3.6-14.2) 0.2 (0.1-0.8)
SDMA > 20 μg/dL 90 5.7 (1.7-19.6) 0.7 (0.6-0.9) 7.9 (2.7-23.6) 0.6 (0.4-0.9) 8.0 (3.2-20.1) 0.4 (0.2-0.9)
Creatinine ≥ 1.0 mg/dL 90 1.8 (1.4-2.5) 0.3 (0.1-0.6) 1.6 (1.3-2.1) 0.2 (0.1-0.9) 1.6 (1.2-2.1) 0.2 (0.0-1.5)
Creatinine ≥ 1.1 mg/dL 90 2.6 (1.7-3.9) 0.2 (0.1-0.5) 2.2 (1.6-3.1) 0.2 (0.1-0.7) 2.0 (1.5-2.8) 0.2 (0.0-1.2)
Creatinine ≥ 1.2 mg/dL 90 3.8 (2.1-6.8) 0.4 (0.2-0.6) 3.3 (2.1-5.2) 0.2 (0.1-0.6) 3.0 (2.0-4.5) 0.1 (0.0-0.9)
Creatinine ≥ 1.3 mg/dL 90 5.4 (2.6-11.4) 0.4 (0.3-0.7) 5.0 (2.9-8.7) 0.2 (0.1-0.6) 4.0 (2.5-6.3) 0.1 (0.0-0.8)
Creatinine ≥ 1.4 mg/dL 90 10.4 (2.5-44.3) 0.7 (0.5-0.9) 8.9 (3.1-25.9) 0.5 (0.3-0.8) 9.3 (3.9-22.3) 0.3 (0.1-0.8)
Creatinine ≥ 1.5 mg/dL 90 — 0.9 (0.8-1.0) 2.0 (0.2-20.9) 1.0 (0.9-1.1) 4.0 (0.4-40.3) 0.9 (0.8-1.1)
Notes: The LR+ is the probability of a dog with decreased GFR to have the analyte exceeding cutoff divided by the probability of a dog with normal GFR to
have the same analyte exceeding cutoff (LR+ = sensitivity1−specificityÞ. A LR+ greater than 1 indicates that the test result is associated with decreased GFR. The higher
the LR+, the stronger the association. The LR− is the probability of a dog with decreased GFR to have the analyte below the cutoff divided by the
probability of a dog with normal GFR to have the same analyte below the cutoff (LR−= 1−sensitivityspecificity Þ. A likelihood ratio less than 1 indicates that the result is
associated with absence of the disease. The lower the LR− (trending towards 0), the stronger the exclusion.
Abbreviations: GFR, glomerular filtration rate; SDMA, symmetric dimethylarginine.
F IGURE 4 Receiver operating characteristic curve for serum
symmetric dimethylarginine detecting a glomerular filtration rate
(GFR) decrease of ≥20%, ≥30%, and ≥40% below the mean GFR of a
dog's body weight category. AUC, area under the curve
F IGURE 5 Receiver operating characteristic curve for serum
creatinine detecting a glomerular filtration rate (GFR) decrease of
≥20%, ≥30%, and ≥40% below the mean GFR of a dog's body weight
category. AUC, area under the curve
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relationships between GFR and both markers were nonlinear. A likely
explanation for this different relationship is that the population of dogs in
our study either had normal or mildly reduced kidney function, resulting in
a limited range of GFR results, whereas the population of dogs in the ear-
lier study included dogs that were azotemic.19 The correlations between
SDMAandGFR and between serum creatinine andGFR in this studywere
lower than previously reported.19 Again, a likely explanation for this is the
limited range of GFR results in our population. Another possible explana-
tion is that the dogs in our study represented a heterogeneous population
of client-owned dogs, which were ultimately diagnosed with a variety of
medical conditions that could have influenced serum creatinine or SDMA
concentrations.
Increased SDMA above the reference interval of 14 μg/dL was
sensitive (90%) but nonspecific (50%) for detection of a ≥40% GFR
decrease below the mean GFR of the canine body weight category. This
percentage decrease in GFR is considered a clear indication of a renal
etiology of disease. Using ROC curve analysis and Youden's J statistic,
the optimal SDMA cutoff for assessing for a GFR decrease of ≥40%
was 18 μg/dL (sensitivity 90%, specificity 83%). Given the low specific-
ity of SDMA >14 μg/dL for detecting a GFR decrease of ≥40%, the
authors suggest that applying a cutoff of >18 μg/dL could be more
appropriate than the previously described reference interval when used
to test for decreased renal function in dogs with a clinical presentation
suggestive of non-azotemic renal disease as a cause for polyuria and
polydipsia or other urinary tract signs. When using SDMA to screen for
non-azotemic renal disease, if using the traditional reference interval of
>14 μg/dL, only half (50%) of the cases will ultimately have a GFR
decrease of ≥40% below the mean GFR for the canine body weight cat-
egory. The specificity is greatly improved (83%), while maintaining the
same sensitivity (90%), if the SDMA cutoff is changed to >18 μg/dL
even if serum creatinine is within the reference interval.
In 54% of dogs who had SDMA measured above reference inter-
val (>14 μg/dL), GFR was increased or <20% decreased below the
mean GFR of the canine body weight category. The fact that more
than half of the dogs with increased SDMA did not have a GFR result
consistent with decreased renal function raises concern for false-
positive results in this scenario had SDMA alone been used (as a sin-
gle data point) to interpret renal function in dogs being screened for
non-azotemic renal disease. Evaluating the final diagnosis from
follow-up clinical data for dogs with increased SDMA but normal GFR
estimation results, several dogs fell into the category of idiopathic der-
matopathy. Many of these cases had GFR estimation performed to
screen for AKI due to the presence of skin lesions, reflecting the
recent emergence of cutaneous and renal glomerular vasculopathy in
the United Kingdom.26 Three dogs with increased SDMA and an
increase or ≤20% decrease from the mean GFR of their body weight
category were considered clinically normal by the submitting veteri-
narians at the time of follow-up; unfortunately, this assessment was
based on spontaneous resolution of clinical signs (polyuria-polydipsia
in all cases) rather than on longitudinal monitoring of their kidney
function. Therefore, the authors cannot exclude the possibility that
these dogs could have had undetected kidney disease at the time of
follow-up and that progression of kidney disease would have been
documented either through serial assessment of serum creatinine
concentration or repeat GFR estimation. The ultimate classification of
these dogs as normal can therefore be questioned. Serial assessment
of SDMA and GFR estimation in these dogs would have been of inter-
est to determine the long-term outcome of carefully monitored renal
function in these cases with initially increased SDMA concentrations.
However, this was unfortunately not possible within the scope of this
study.
A common rationale for measuring SMDA or performing GFR
estimation in dogs is to determine whether a renal etiology exists for
presenting clinical signs, typically polyuria and polydipsia, in non-
azotemic patients. All dogs included in the statistical analysis for this
study were non-azotemic at the time of GFR estimation. With ROC
curve analysis and Youden's J statistic, the optimal serum creatinine
cutoff for assessing for a GFR decrease of ≥40% was ≥1.36 mg/dL
(sensitivity 80%, specificity 89%). This cutoff for serum creatinine had
lower sensitivity (80% vs. 90%) but greater specificity (89% vs. 83%)
to using a cut-off of >18 mg/dL for SMDA for detection of a GFR
decrease of ≥40%. The presence of a concurrent serum creatinine
concentration of ≥1.36 mg/dL in conjunction with an SDMA result of
>18 mg/dL had greater specificity (98%) but lower sensitivity (70%)
for detecting a GFR decrease of ≥40% than documentation of either
serum creatinine ≥1.36 mg/dL or SDMA >18 mg/dL alone.
The authors acknowledge that using breed-specific reference
intervals for serum creatinine or serial monitoring of serum creatinine
concentrations may have increased the sensitivity of creatinine for
detection of decreased renal function without the requirement for
GFR estimation in some of the dogs in the present study. However,
breed-specific reference intervals and serial creatinine concentrations
from the same laboratory were not available, so it was not possible to
compare the sensitivity of SMDA to the use of breed-specific creati-
nine reference intervals or to serial creatinine measurements. Such a
comparison could be a focus for a future study.
The authors recognize the limitations of this study. Firstly, this
study relied on submitting veterinarians following a standard iohexol
clearance protocol. To the best of the authors' knowledge, the rec-
ommended protocol was followed by submitting veterinarians, but we
acknowledge the possibility that in some cases, deviation from the
protocol could have occurred with subsequent effects on the results.
The canine-specific correction formula used to calculate estimated
GFR in this study was derived from data from dogs undergoing sur-
gery for pyometra,27 whereas our population was much more hetero-
geneous. As the correction formula has not been validated in a
population as varied as in this study, it is possible that the extrapola-
tion of this correction formula to a heterogeneous population could
have decreased the accuracy of GFR estimation calculations. Symmet-
ric dimethylarginine samples in the study were submitted to 2 different
laboratories: Idexx Wetherby (UK, n = 96) and Idexx Ludwigsburg
(Germany, n = 17). The reference intervals, analyzers, and methodol-
ogy used to measure SDMA were identical in both laboratories; as
such, the authors acknowledge that the fact that SDMA was mea-
sured at 2 different laboratories, albeit from the same company, could
have affected some of the results in this study, but believe it is
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unlikely that this impacts the validity of the results. A further limita-
tion relates to the storage times of serum samples for serum creati-
nine and SDMA measurement. Although the median time these serum
samples were stored in a −80C freezer was 166 days, some samples
were stored for a much longer time (up to 1360 days) which could
have impacted results if sample preservation was compromised.
The authors also acknowledge the limitations of using GFR esti-
mation as the gold standard for assessment of renal function. Glo-
merular filtration rate varies with the size of the dog (somewhat
accounted for by body weight)12 and with breed,28 which could lead
to misinterpretation of renal function of a dog if its size and breed is
not taken into account. It is also possible that comparing a dog's GFR
to the mean GFR of the dog's body weight category13 may lead to
misinterpretation of renal function of a dog; the mean GFR of their
body weight category may not reflect what is a normal GFR for an
individual dog, which could lead to overestimation or underestima-
tion of any reduction in GFR. Information on body condition score
and muscle condition score was not available for the dogs in our
study population. As actual, rather than ideal, body weight was used
to classify dogs into weight quartiles, it is possible that some dogs
could have been misclassified into a higher or lower body weight
quartile, potentially leading to comparison of their GFR value to an
inappropriate mean. In addition, 1 dog's body weight did not fall
within the ranges of the defined body weight categories,13 and
therefore this dog was included in the body weight category to which
its body weight was closest. The authors acknowledge the possibility
that this dog could have been misclassified and its GFR compared to
an inappropriate mean.
In conclusion, SDMA can be a sensitive marker for detecting
decreased renal function in non-azotemic dogs depending on the cut-
off used. In non-azotemic dogs being screened for decreased renal
function, defined as a GFR decrease ≥40% below the mean GFR of
their body weight category, using a cutoff of >18 μg/dL rather than
the traditional cutoff of >14 μg/dL increases the specificity of SDMA,
without compromising sensitivity in this population.
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